Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
Diffuse Large Cell B-lymphoma
DRUG: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
Complete response rate (CR rate), Percentage of subjects with complete (CR) per 2014 Lugano criteria., 1 year
Overall response rate (ORR), Percentage of subjects with complete (CR) or partial response (PR) according to 2014 Lugano Criteria., 1 year|Progression-free survival (PFS), Time from randomization or first dose to disease progression or death from any cause, whichever occurs first, as determined by the 2014 Lugano Criteria., 1 year|Duration of Response (DOR), The time from first achievement of response, to disease progression or death from any cause, whichever comes first, was determined according to the 2014 Lugano criteria., 1 year|Time to Response (TTR), Time from randomization or first dose of trial drug to the first evaluation of PR or CR, whichever occurs first., 1 year|Overall survival (OS), From randomization to the time of death from any cause., 3 years|Half-life (t1/2), Time required for the amount of drug in the body or blood concentration to be reduced by half., Pre-dose, 5 minutes, 24, 72, 120 and 168 hours post dose on day 1 of cycles 2, 4; pre-dose, 5 minutes post dose on day 1 of cycles 3, 8; once at the end of treatment, each cycle is 21 days|Area under the plasma concentration-time curve (AUC0-last), Area under the dynamic curve of plasma concentration over time., Pre-dose, 5 minutes, 24, 72, 120 and 168 hours post dose on day 1 of cycles 2, 4; pre-dose, 5 minutes post dose on day 1 of cycles 3, 8; once at the end of treatment, each cycle is 21 days|Apparent clearance (CL), The rate at which the drug is cleared from the body., Pre-dose, 5 minutes, 24, 72, 120 and 168 hours post dose on day 1 of cycles 2, 4; pre-dose, 5 minutes post dose on day 1 of cycles 3, 8; once at the end of treatment, each cycle is 21 days|Apparent volume of distribution at terminal phase (Vz), The volume of body fluid required to distribute the drug in the body according to the plasma drug concentration at this time after the drug distribution in the plasma and tissues has reached equilibrium., Pre-dose, 5 minutes, 24, 72, 120 and 168 hours post dose on day 1 of cycles 2, 4; pre-dose, 5 minutes post dose on day 1 of cycles 3, 8; once at the end of treatment, each cycle is 21 days|Trough plasma concentration (Cmin), Maximum blood concentration achieved by drug administration., Pre-dose, 5 minutes, 24, 72, 120 and 168 hours post dose on day 1 of cycles 2, 4; pre-dose, 5 minutes post dose on day 1 of cycles 3, 8; once at the end of treatment, each cycle is 21 days|Anti-drug antibody (ADA ) incidence, Immunogenicity test: Anti-drug antibody (ADA ) incidence., 2 years
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.